Gastroenterology Education and CPD for trainees and specialists » ASCO GI: Drug Active in Resistant GIST

- Gastroenterology Education and CPD for trainees and specialists - https://www.gastrotraining.com -

ASCO GI: Drug Active in Resistant GIST

SAN FRANCISCO (MedPage Today) — Two-thirds of patients with advanced gastrointestinal stromal tumors (GIST) achieved disease control after second- and third-line treatment with sorafenib (Nexavar), results of a small clinical trial showed.

Article printed from Gastroenterology Education and CPD for trainees and specialists: https://www.gastrotraining.com